| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Brief Communications |
1 Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
2 Mallinckrodt Medical, St. Louis, Missouri
3 Department of Internal Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
ABSTRACT
The 14-amino-acid peptide bombesin (BN) has a high affinity for the gastrin-releasing peptide (GRP) receptor that is expressed by a variety of tumors. Recently, high densities of GRP receptors were identified by in vitro receptor autoradiography in human prostate and breast carcinomas using [125I-Tyr4]BN as radioligand. Radiometal-labeled diethylenetriaminepentaacetic acid (DTPA)-BN derivatives are potentially useful radioligands for receptor-targeted scintigraphy and radiotherapy of GRP receptor-expressing tumors. Methods: [DTPA-Pro1,Tyr4]BN (A), [DOTA-Pro1,Tyr4]BN (B), [DTPA-
-Lys3,Tyr4]BN (C), and [DOTA--Lys3,Tyr4]BN (D) (where DOTA is dodecanetetraacetic acid) were synthesized and studied for competition with binding of [125I-Tyr4]BN to the GRP receptor. The 111In-labeled BN analogs were studied in vitro for binding and internalization by GRP receptor-expressing CA20948 and AR42J pancreatic tumor cells as well as in vivo for tissue distribution in rats. Specific tissue binding was tested by coinjection of 0.1 mg [Tyr4]BN. Results: All BN analogs competitively inhibited the binding of [125I-Tyr4]BN to the GRP receptor with 50% inhibitory concentration values in the range of 2–9 nmol/L. All 111In-labeled analogs showed high and specific time- and temperature-dependent binding and internalization by CA20948 and AR42J cells. In in vivo studies, high and specific binding was found in GRP receptor-positive tissues such as pancreas (0.90, 1.2, 0.54, and 0.79 percentage injected dose per gram for A–D, respectively). In a rat model, the AR42J tumor could clearly be visualized by scintigraphy using [111In-DTPA-Pro1,Tyr4]BN as the radioligand. Although [111In-DOTA-Pro1,Tyr4]BN showed the highest uptake of radioactivity in GRP receptor-positive tissues as well as higher target-to-blood ratios, [111In-DTPA-Pro1,Tyr4]BN was easier to handle and is more practical to use. Therefore, we decided to start phase I studies with this DTPA-conjugated radioligand. Conclusion: [111In-DTPA-Pro1,Tyr4]BN is a promising radioligand for scintigraphy of GRP receptor-expressing tumors. We are currently performing a phase I study on patients with invasive prostate carcinoma.
Key Words: bombesin analogs • gastrin-releasing peptide receptor • receptor scintigraphy • DTPA • DOTA
This article has been cited by other articles:
|
|
 |
|
  S. M. OKARVI and I. A. JAMMAZ Design, Synthesis, Radiolabeling and In Vitro and In Vivo Characterization of Tumor-antigen- and Antibody-derived Peptides for the Detection of Breast Cancer Anticancer Res, April 1, 2009; 29(4): 1399 - 1409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Lantry, E. Cappelletti, M. E. Maddalena, J. S. Fox, W. Feng, J. Chen, R. Thomas, S. M. Eaton, N. J. Bogdan, T. Arunachalam, et al. 177Lu-AMBA: Synthesis and Characterization of a Selective 177Lu-Labeled GRP-R Agonist for Systemic Radiotherapy of Prostate Cancer J. Nucl. Med., July 1, 2006; 47(7): 1144 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Tolmachev, F. Y. Nilsson, C. Widstrom, K. Andersson, D. Rosik, L. Gedda, A. Wennborg, and A. Orlova 111In-Benzyl-DTPA-ZHER2:342, an Affibody-Based Conjugate for In Vivo Imaging of HER2 Expression in Malignant Tumors J. Nucl. Med., May 1, 2006; 47(5): 846 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Achilefu, S. Bloch, M. A. Markiewicz, T. Zhong, Y. Ye, R. B. Dorshow, B. Chance, and K. Liang Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression PNAS, May 31, 2005; 102(22): 7976 - 7981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schuhmacher, H. Zhang, J. Doll, H. R. Macke, R. Matys, H. Hauser, M. Henze, U. Haberkorn, and M. Eisenhut GRP Receptor-Targeted PET of a Rat Pancreas Carcinoma Xenograft in Nude Mice with a 68Ga-Labeled Bombesin(6-14) Analog J. Nucl. Med., April 1, 2005; 46(4): 691 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Maecke, M. Hofmann, and U. Haberkorn 68Ga-Labeled Peptides in Tumor Imaging J. Nucl. Med., January 1, 2005; 46(1_suppl): 172S - 178S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Capello, E. P. Krenning, B. F. Bernard, W. A.P. Breeman, M. P. van Hagen, and M. de Jong Increased Cell Death After Therapy with an Arg-Gly-Asp-Linked Somatostatin Analog J. Nucl. Med., October 1, 2004; 45(10): 1716 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang, J. Chen, C. Waldherr, K. Hinni, B. Waser, J. C. Reubi, and H. R. Maecke Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors Cancer Res., September 15, 2004; 64(18): 6707 - 6715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, R. Park, Y. Hou, M. Tohme, A. H. Shahinian, J. R. Bading, and P. S. Conti microPET and Autoradiographic Imaging of GRP Receptor Expression with 64Cu-DOTA-[Lys3]Bombesin in Human Prostate Adenocarcinoma Xenografts J. Nucl. Med., August 1, 2004; 45(8): 1390 - 1397. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
